Hojoon Sohn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hojoon Sohn has a total of 260 co-authors. Here are the top co-authors by number of shared publications:
Austin Tucker
Department of Global Health and Population, Harvard T H Chan School of Public Health, Boston, MA, USA
4 shared publicationsDavid W. Dowdy
Affiliations Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, United States of America
4 shared publications- David W. Dowdy
Johns Hopkins University
4 shared publications - Hongjo Choi
Division of Health Policy and Management, Korea University College of Health Science, Seoul, Republic of Korea
4 shared publications - Akash Malhotra
Department of Global Health, University of Washington, Seattle, WA, USA.
3 shared publications David W Dowdy
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health , Baltimore, MD
3 shared publications
Latest Publications
- Open Access
- 13 December 2025
- Published by Korean Society of Epidemiology in Epidemiology and Health
- Vol. 47, e2025071
Cohort profile: the KDCA-Tuberculosis-NHIS cohort linking tuberculosis surveillance and health insurance data in Korea
Despite a steady decline in incidence, tuberculosis (TB) remains a substantial public health burden in Korea, particularly among older adults. Existing national TB surveillance systems lack sufficiently comprehensive data to assess long-term outcomes and health disparities. The K-TB-N cohort integrates data from 3 national sources: the Korean Tuberculosis Surveillance System (2011-2022), the National Health Insurance Database (2010-2022), and mortality data from Statistics Korea (2010-2022). After data cleaning and linkage, the final cohort included 373,812 patients (375,440 episodes) with either drug-susceptible TB or drug- resistant TB. TB notifications declined by approximately 60% over the study period, while the median patient age continued to rise. Treatment success improved over time, accompanied by reductions in lost to follow-up. However, mortality during treatment increased, with more than half of deaths attributed to non-TB causes such as pneumonia, cancer, and cardiovascular disease. Post-treatment mortality also remained high, particularly among patients with drug-resistant TB. The K-TB-N cohort provides a comprehensive, linked dataset for advancing research on TB epidemiology, treatment outcomes, comorbidities, and health disparities. It enables evaluations of public health interventions, long-term prognosis, and strategies for post-TB care. This cohort will remain a valuable resource for shaping data-driven TB control policies in aging and high-burden settings.
- 13 December 2025
- Published by Korean Society of Epidemiology in Epidemiology and Health
- Vol. 47, e2025071
Open AccessCohort profile: the KDCA-Tuberculosis-NHIS cohort linking tuberculosis surveillance and health insurance data in Korea
Despite a steady decline in incidence, tuberculosis (TB) remains a substantial public health burden in Korea, particularly among older adults. Existing national TB surveillance systems lack sufficiently comprehensive data to assess long-term outcomes and health disparities. The K-TB-N cohort integrates data from 3 national sources: the Korean Tuberculosis Surveillance System (2011-2022), the National Health Insurance Database (2010-2022), and mortality data from Statistics Korea (2010-2022). After data cleaning and linkage, the final cohort included 373,812 patients (375,440 episodes) with either drug-susceptible TB or drug- resistant TB. TB notifications declined by approximately 60% over the study period, while the median patient age continued to rise. Treatment success improved over time, accompanied by reductions in lost to follow-up. However, mortality during treatment increased, with more than half of deaths attributed to non-TB causes such as pneumonia, cancer, and cardiovascular disease. Post-treatment mortality also remained high, particularly among patients with drug-resistant TB. The K-TB-N cohort provides a comprehensive, linked dataset for advancing research on TB epidemiology, treatment outcomes, comorbidities, and health disparities. It enables evaluations of public health interventions, long-term prognosis, and strategies for post-TB care. This cohort will remain a valuable resource for shaping data-driven TB control policies in aging and high-burden settings.
- Open Access
- 3 November 2025
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 8 (11) , e2543278
Long-Term Health and Cost Outcomes of a 24-Week Multicomponent Frailty Intervention in Older Adults
Importance: While multicomponent frailty interventions have demonstrated short-term effectiveness, evidence on long-term health and cost outcomes is limited. Objective: To evaluate the 66-month health and cost outcomes of a multicomponent frailty intervention for older adults in rural Korea. Design, Setting, and Participants: This economic evaluation used data from the Aging Study of Pyeongchang Rural Area–Intervention Study, a nonrandomized clinical trial conducted from August 2015 to January 2017. Individual-level data were linked to National Health Insurance Service claims data through December 2021, and analyses were performed from June 2024 to August 2025. Participants were socioeconomically vulnerable adults aged 65 years and older living alone or receiving medical aid in a rural Korean community. Volunteers were enrolled in the intervention, while those who declined enrollment served as controls. Propensity score matching was performed using frailty, functional status, demographics, comorbidities, depression, and prior health service use. Intervention: A 24-week multicomponent program including structured exercise and nutrition, with depression management, deprescribing, and home hazard reduction provided by risk profile. Main Outcomes and Measures: Survival analyses assessed a composite of all-cause mortality or long-term care insurance eligibility over 66 months. Cost outcomes included cumulative health service–use costs and cost:benefit ratios, calculated as incremental costs relative to intervention costs. Results: Among 383 eligible adults, 187 volunteered to participate and 196 individuals served as controls; NHIS linkage was successful for 181 (96.8%) and 192 (98.0%) participants, respectively. Among 119 matched pairs (238 [68.9%] aged ≥75 years; 177 [74.4%] female), participants had longer composite outcome-free survival at 66 months (mean difference, 6.53 [95% CI, 1.38-11.68] months). Health service–use costs were consistently lower in the participants group, mainly from reduced hospitalizations and long-term care use, with per-person savings of $7688 (95% CI, 1197-14 615) at 66 months, representing a cost:benefit ratio of 8.82. Conclusions and Relevance: In this economic evaluation of a nonrandomized clinical trial, participants in a 24-week multicomponent intervention had longer survival free from death or long-term care eligibility and had lower health service–use costs over 66 months. These findings support consideration of broader implementation of community-based frailty interventions in older adults.
- 3 November 2025
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 8 (11) , e2543278
Open AccessLong-Term Health and Cost Outcomes of a 24-Week Multicomponent Frailty Intervention in Older Adults
Importance: While multicomponent frailty interventions have demonstrated short-term effectiveness, evidence on long-term health and cost outcomes is limited. Objective: To evaluate the 66-month health and cost outcomes of a multicomponent frailty intervention for older adults in rural Korea. Design, Setting, and Participants: This economic evaluation used data from the Aging Study of Pyeongchang Rural Area–Intervention Study, a nonrandomized clinical trial conducted from August 2015 to January 2017. Individual-level data were linked to National Health Insurance Service claims data through December 2021, and analyses were performed from June 2024 to August 2025. Participants were socioeconomically vulnerable adults aged 65 years and older living alone or receiving medical aid in a rural Korean community. Volunteers were enrolled in the intervention, while those who declined enrollment served as controls. Propensity score matching was performed using frailty, functional status, demographics, comorbidities, depression, and prior health service use. Intervention: A 24-week multicomponent program including structured exercise and nutrition, with depression management, deprescribing, and home hazard reduction provided by risk profile. Main Outcomes and Measures: Survival analyses assessed a composite of all-cause mortality or long-term care insurance eligibility over 66 months. Cost outcomes included cumulative health service–use costs and cost:benefit ratios, calculated as incremental costs relative to intervention costs. Results: Among 383 eligible adults, 187 volunteered to participate and 196 individuals served as controls; NHIS linkage was successful for 181 (96.8%) and 192 (98.0%) participants, respectively. Among 119 matched pairs (238 [68.9%] aged ≥75 years; 177 [74.4%] female), participants had longer composite outcome-free survival at 66 months (mean difference, 6.53 [95% CI, 1.38-11.68] months). Health service–use costs were consistently lower in the participants group, mainly from reduced hospitalizations and long-term care use, with per-person savings of $7688 (95% CI, 1197-14 615) at 66 months, representing a cost:benefit ratio of 8.82. Conclusions and Relevance: In this economic evaluation of a nonrandomized clinical trial, participants in a 24-week multicomponent intervention had longer survival free from death or long-term care eligibility and had lower health service–use costs over 66 months. These findings support consideration of broader implementation of community-based frailty interventions in older adults.
- Open Access
- 30 April 2025
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 5 (4) , e0004466
Cost and cost-effectiveness of pediatric home-based versus facility-based TB Preventive Treatment in Ethiopia (CHIP-TB)
Tuberculosis preventive treatment (TPT) is an essential intervention recommended for all child contacts in Ethiopia under 15 years who are at risk of tuberculosis (TB) infection. We conducted a cost and cost-effectiveness analysis of home-based versus facility-based TPT provision for child contacts in Ethiopia. As part of the CHIP TB trial, a pragmatic, cluster-randomized trial conducted at eighteen clinics in Ethiopia, clinics were randomized to either a home-based model (intervention arm), administered by community health workers, or a facility-based model (standard of care) for managing child contacts. Cost data were collected from both a health service perspective and a household perspective, capturing all costs relevant to TPT. Costs were evaluated on a per-household basis, with the primary outcome being the difference in median costs per household initiating TPT. A secondary outcome assessed the cost-effectiveness as the incremental cost per additional child contact starting TPT. Probabilistic sensitivity analyses (PSA) were conducted to examine the robustness of findings. At an average cost of US$18.92 per household managed, Home-based contact management, including TPT delivery was cost-saving compared to facility-based TPT delivery (US$27.24 per household managed) assessed based on the partial-societal perspectives, largely due to reductions in household out-of-pocket costs. The home-based strategy was both less costly and had increased TPT initiation in 61.5% of the scenarios assessed in the PSA. Home-based contact management is a cost-saving alternative for households and provides comparable initiation rates to facility-based care, making it a feasible approach to improve TB preventive treatment accessibility. Although it does not entirely replace facility-based care, a hybrid model that respects household preferences and allows flexibility in delivery could enhance TB care access for socio-economically disadvantaged households, potentially reducing health inequities. The trial was registered on clinicaltrials.gov NCT04369326 on April 30, 2020. https://clinicaltrials.gov/study/NCT04369326.
- 30 April 2025
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 5 (4) , e0004466
Open AccessCost and cost-effectiveness of pediatric home-based versus facility-based TB Preventive Treatment in Ethiopia (CHIP-TB)
Tuberculosis preventive treatment (TPT) is an essential intervention recommended for all child contacts in Ethiopia under 15 years who are at risk of tuberculosis (TB) infection. We conducted a cost and cost-effectiveness analysis of home-based versus facility-based TPT provision for child contacts in Ethiopia. As part of the CHIP TB trial, a pragmatic, cluster-randomized trial conducted at eighteen clinics in Ethiopia, clinics were randomized to either a home-based model (intervention arm), administered by community health workers, or a facility-based model (standard of care) for managing child contacts. Cost data were collected from both a health service perspective and a household perspective, capturing all costs relevant to TPT. Costs were evaluated on a per-household basis, with the primary outcome being the difference in median costs per household initiating TPT. A secondary outcome assessed the cost-effectiveness as the incremental cost per additional child contact starting TPT. Probabilistic sensitivity analyses (PSA) were conducted to examine the robustness of findings. At an average cost of US$18.92 per household managed, Home-based contact management, including TPT delivery was cost-saving compared to facility-based TPT delivery (US$27.24 per household managed) assessed based on the partial-societal perspectives, largely due to reductions in household out-of-pocket costs. The home-based strategy was both less costly and had increased TPT initiation in 61.5% of the scenarios assessed in the PSA. Home-based contact management is a cost-saving alternative for households and provides comparable initiation rates to facility-based care, making it a feasible approach to improve TB preventive treatment accessibility. Although it does not entirely replace facility-based care, a hybrid model that respects household preferences and allows flexibility in delivery could enhance TB care access for socio-economically disadvantaged households, potentially reducing health inequities. The trial was registered on clinicaltrials.gov NCT04369326 on April 30, 2020. https://clinicaltrials.gov/study/NCT04369326.
- Open Access
- 12 September 2024
- Published by Korean Society of Epidemiology in Epidemiology and Health
- Vol. 46, e2024076
Homelessness and mortality: gender, age, and housing status inequity in Korea
OBJECTIVES: We compared mortality rates among various housing statuses within the homeless population and investigated factors contributing to their deaths, including housing status, gender, and age.METHODS: Using a comprehensive multi-year dataset (n=15,445) curated by the National Tuberculosis Screening and Case Management Programs, matched with the 2019-2021 Vital Statistics Death Database and National Health Insurance claims data, we calculated age-standardized mortality rates and conducted survival analysis to estimate differences in mortality rates based on housing status.RESULTS: The mortality rate among the homeless population was twice as high as that of the general population, at 1,159.6 per 100,000 compared to 645.8 per 100,000, respectively. Cancer and cardiovascular diseases were the primary causes of death. Furthermore, individuals residing in shelter facilities faced a significantly higher risk of death than those who were rough sleeping, with an adjusted hazard ratio of 1.70 (95% confidence interval, 1.37 to 2.11). This increased risk was especially pronounced in older adults and women.CONCLUSIONS: The study highlights the urgent need for targeted interventions, as the homeless population faces significantly higher mortality rates. Older adults and women in shelter facilities are at the highest risk.
- 12 September 2024
- Published by Korean Society of Epidemiology in Epidemiology and Health
- Vol. 46, e2024076
Open AccessHomelessness and mortality: gender, age, and housing status inequity in Korea
OBJECTIVES: We compared mortality rates among various housing statuses within the homeless population and investigated factors contributing to their deaths, including housing status, gender, and age.METHODS: Using a comprehensive multi-year dataset (n=15,445) curated by the National Tuberculosis Screening and Case Management Programs, matched with the 2019-2021 Vital Statistics Death Database and National Health Insurance claims data, we calculated age-standardized mortality rates and conducted survival analysis to estimate differences in mortality rates based on housing status.RESULTS: The mortality rate among the homeless population was twice as high as that of the general population, at 1,159.6 per 100,000 compared to 645.8 per 100,000, respectively. Cancer and cardiovascular diseases were the primary causes of death. Furthermore, individuals residing in shelter facilities faced a significantly higher risk of death than those who were rough sleeping, with an adjusted hazard ratio of 1.70 (95% confidence interval, 1.37 to 2.11). This increased risk was especially pronounced in older adults and women.CONCLUSIONS: The study highlights the urgent need for targeted interventions, as the homeless population faces significantly higher mortality rates. Older adults and women in shelter facilities are at the highest risk.
- 14 February 2024
- Published by Oxford University Press (OUP) in International Journal of Epidemiology
- Vol. 53 (2)
Active case-finding of tuberculosis compared with symptom-driven standard of care: a modelling analysis
Background: In settings with large case detection gaps, active case-finding (ACF) may play a critical role in the uberculosis (TB) response. However, ACF is resource intensive, and its effectiveness depends on whether people detected with TB through ACF might otherwise spontaneously resolve or be diagnosed through routine care. We analysed the potential effectiveness of ACF for TB relative to the counterfactual scenario of routine care alone. Methods: We constructed a Markov simulation model of TB natural history, diagnosis, symptoms, ACF and treatment, using a hypothetical reference setting using data from South East Asian countries. We calibrated the model to empirical data using Bayesian methods, and simulated potential 5-year outcomes with an ‘aspirational’ ACF intervention (reflecting maximum possible effectiveness) compared with the standard-of-care outcomes. Results: Under the standard of care, 51% (95% credible interval, CrI: 31%, 75%) of people with prevalent TB at baseline were estimated to be diagnosed and linked to care over 5 years. With aspirational ACF, this increased to 88% (95% CrI: 84%, 94%). Most of this difference represented people who were diagnosed and treated through ACF but experienced spontaneous resolution under standard-of-care. Aspirational ACF was projected to reduce the average duration of TB disease by 12 months (95% CrI: 6%, 18%) and TB-associated disability-adjusted life-years by 71% (95% CrI: 67%, 76%). Conclusion: These data illustrate the importance of considering outcomes in a counterfactual standard of care scenario, as well as trade-offs between overdiagnosis and averted morbidity through earlier diagnosis—not just for TB, but for any disease in which population-based screening is recommended.
- 14 February 2024
- Published by Oxford University Press (OUP) in International Journal of Epidemiology
- Vol. 53 (2)
Active case-finding of tuberculosis compared with symptom-driven standard of care: a modelling analysis
Background: In settings with large case detection gaps, active case-finding (ACF) may play a critical role in the uberculosis (TB) response. However, ACF is resource intensive, and its effectiveness depends on whether people detected with TB through ACF might otherwise spontaneously resolve or be diagnosed through routine care. We analysed the potential effectiveness of ACF for TB relative to the counterfactual scenario of routine care alone. Methods: We constructed a Markov simulation model of TB natural history, diagnosis, symptoms, ACF and treatment, using a hypothetical reference setting using data from South East Asian countries. We calibrated the model to empirical data using Bayesian methods, and simulated potential 5-year outcomes with an ‘aspirational’ ACF intervention (reflecting maximum possible effectiveness) compared with the standard-of-care outcomes. Results: Under the standard of care, 51% (95% credible interval, CrI: 31%, 75%) of people with prevalent TB at baseline were estimated to be diagnosed and linked to care over 5 years. With aspirational ACF, this increased to 88% (95% CrI: 84%, 94%). Most of this difference represented people who were diagnosed and treated through ACF but experienced spontaneous resolution under standard-of-care. Aspirational ACF was projected to reduce the average duration of TB disease by 12 months (95% CrI: 6%, 18%) and TB-associated disability-adjusted life-years by 71% (95% CrI: 67%, 76%). Conclusion: These data illustrate the importance of considering outcomes in a counterfactual standard of care scenario, as well as trade-offs between overdiagnosis and averted morbidity through earlier diagnosis—not just for TB, but for any disease in which population-based screening is recommended.
- Open Access
- 18 December 2023
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 45 (1) , 130-139
A Pragmatic Randomized clinical trial: twice-weekly vs. thrice-weekly Incident hemoDialysis in Elderly patients (PRIDE): study protocol
The optimal frequency for hemodialysis in older adults with end-stage kidney disease (ESKD) has not been established. This study aims to investigate whether a twice-weekly dialysis schedule using an incremental approach can reduce hospitalization rates in the elderly with incident dialysis, compared with conventional thrice-weekly dialysis. We have designed a pragmatic randomized controlled trial to compare the effects of twice-weekly versus thrice-weekly hemodialysis in 428 ESKD individuals (dropout rate 20%) aged 60 years or older with residual kidney function (urine output, >500 mL/ day). The trial will be conducted across 18 referral hospital-based dialysis centers in Korea. Individual participants will be randomized to either a twice-weekly (with incremental approach) or thrice-weekly dialysis group and will be followed up for 24 months. The primary outcome of the study is all-cause hospitalization rate, while secondary outcomes include dialysis-specific hospitalization rates, mortality, quality of life, frailty, and cost-effectiveness. Participants have the flexibility to transfer to other dialysis centers as needed. The decision to increase dialysis frequency will be made by the treating physicians. The study is ongoing and will be completed in May 2026. This study will provide valuable insights into the benefits and risks of twice-weekly dialysis with an incremental approach in elderly with residual kidney function compared to thrice-weekly dialysis.
- 18 December 2023
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 45 (1) , 130-139
Open AccessA Pragmatic Randomized clinical trial: twice-weekly vs. thrice-weekly Incident hemoDialysis in Elderly patients (PRIDE): study protocol
The optimal frequency for hemodialysis in older adults with end-stage kidney disease (ESKD) has not been established. This study aims to investigate whether a twice-weekly dialysis schedule using an incremental approach can reduce hospitalization rates in the elderly with incident dialysis, compared with conventional thrice-weekly dialysis. We have designed a pragmatic randomized controlled trial to compare the effects of twice-weekly versus thrice-weekly hemodialysis in 428 ESKD individuals (dropout rate 20%) aged 60 years or older with residual kidney function (urine output, >500 mL/ day). The trial will be conducted across 18 referral hospital-based dialysis centers in Korea. Individual participants will be randomized to either a twice-weekly (with incremental approach) or thrice-weekly dialysis group and will be followed up for 24 months. The primary outcome of the study is all-cause hospitalization rate, while secondary outcomes include dialysis-specific hospitalization rates, mortality, quality of life, frailty, and cost-effectiveness. Participants have the flexibility to transfer to other dialysis centers as needed. The decision to increase dialysis frequency will be made by the treating physicians. The study is ongoing and will be completed in May 2026. This study will provide valuable insights into the benefits and risks of twice-weekly dialysis with an incremental approach in elderly with residual kidney function compared to thrice-weekly dialysis.
- Open Access
- 12 December 2023
- Published by Elsevier in Public Health
- Vol. 226, 228-236
Low household income increases the risk of tuberculosis recurrence: a retrospective nationwide cohort study in South Korea
- 12 December 2023
- Published by Elsevier in Public Health
- Vol. 226, 228-236
Open AccessLow household income increases the risk of tuberculosis recurrence: a retrospective nationwide cohort study in South Korea
- Open Access
- 24 August 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (8) , e0290496
Determining cost and placement decisions for moderate complexity NAATs for tuberculosis drug susceptibility testing
Background: Access to drug resistant testing for tuberculosis (TB) remains a challenge in high burden countries. Recently, the World Health Organization approved the use of several moderate complexity automated nucleic acid amplification tests (MC-NAAT) that have performance profiles suitable for placement in a range of TB laboratory tiers to improve drug susceptibility tests (DST) coverage. Methods: We conducted cost analysis of two MC-NAATs with different testing throughput: Lower Throughput (LT, < 24 tests per run) and Higher Throughput (HT, upto 90+ tests per run) for placement in a hypothetical laboratory in a resource limited setting. We used per-test cost as the main indicator to assess 1) drivers of cost by resource types and 2) optimized levels of annual testing volumes for the respective MC-NAATs. Results: The base-case per test cost of $18.52 (range: $13.79 - $40.70) for LT test and $15.37 (range: $9.61 - $37.40) for HT test. Per test cost estimates were most sensitive to the number of testing days per week, followed by equipment costs and TB-specific workloads. In general, HT NAATs were cheaper at all testing volume levels, but at lower testing volumes (less than 2,000 per year) LT tests can be cheaper if the durability of the testing system is markedly better and/or procured equipment costs are lower than that of HT NAAT. Conclusion: Assuming equivalent performance and infrastructural needs, placement strategies for MC-NAATs need to be prioritized by laboratory system’s operational factors, testing demands, and costs.
- 24 August 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (8) , e0290496
Open AccessDetermining cost and placement decisions for moderate complexity NAATs for tuberculosis drug susceptibility testing
Background: Access to drug resistant testing for tuberculosis (TB) remains a challenge in high burden countries. Recently, the World Health Organization approved the use of several moderate complexity automated nucleic acid amplification tests (MC-NAAT) that have performance profiles suitable for placement in a range of TB laboratory tiers to improve drug susceptibility tests (DST) coverage. Methods: We conducted cost analysis of two MC-NAATs with different testing throughput: Lower Throughput (LT, < 24 tests per run) and Higher Throughput (HT, upto 90+ tests per run) for placement in a hypothetical laboratory in a resource limited setting. We used per-test cost as the main indicator to assess 1) drivers of cost by resource types and 2) optimized levels of annual testing volumes for the respective MC-NAATs. Results: The base-case per test cost of $18.52 (range: $13.79 - $40.70) for LT test and $15.37 (range: $9.61 - $37.40) for HT test. Per test cost estimates were most sensitive to the number of testing days per week, followed by equipment costs and TB-specific workloads. In general, HT NAATs were cheaper at all testing volume levels, but at lower testing volumes (less than 2,000 per year) LT tests can be cheaper if the durability of the testing system is markedly better and/or procured equipment costs are lower than that of HT NAAT. Conclusion: Assuming equivalent performance and infrastructural needs, placement strategies for MC-NAATs need to be prioritized by laboratory system’s operational factors, testing demands, and costs.